Search

Treatment with lorlatinib for patients with advanced ALK- and ROS1-rearranged non-small cell lung cancer (ALK+ and ROS1+ NSCLC) is associated with a unique set of adverse events (AEs) often requiring dose reduction. However, the impact of dose reductions on outcomes remains unclear and is mainly limited to analyses from prospective studies of lorlatinib in the first-line setting.

EGFRexon 20 insertions (EGFRex20ins) are a diverse set of mutations in NSCLC that are refractory to tyrosine kinase inhibitors. We describe real-world EGFRex20insdetection patterns in patients with advanced NSCLC in the United States.